Overview of findings from this phase 3 study evaluating isatuximab added to carfilzomib, lenalidomide and dexamethasone.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspective featuring: Douglas Sborov, MD.
The phase 3 IsKia trial compared carfilzomib, lenalidomide, and dexamethasone (KRD) with isatuximab-KRD (Isa-KRD) in patients with transplant-eligible newly diagnosed multiple myeloma. Patients received Isa-KRD or KRD induction, autologous stem cell transplant, then consolidation with their induction regimen, then dose-reduced 3- or 4-drug consolidation for 12 cycles. The primary end point analysis presented was minimal residual disease (MRD) after the first 4 consolidation cycles.
As in most frontline trials, less than 20% of patients had high-risk cytogenetics. MRD-negativity rates (10-5 and 10-6 thresholds) were significantly higher with the Isa-KRD quadruplet vs KRD triplet: 77% and 67% for Isa-KRD vs KRD, respectively. As seen previously, MRD negativity improved over time and was high across cytogenetic-risk subgroups for quadruplet therapy.
Data continue to show superior responses and progression-free survival with quadruplets over triplets up front. The choice between daratumumab vs isatuximab or bortezomib vs carfilzomib should depend on patient factors.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More